Scarica l'app Stockscreener
7.94
7.59%
0.56
Dopo l'orario di chiusura:
8.00
0.06
+0.76%
Precedente Chiudi:
$7.38
Aprire:
$7.95
Volume 24 ore:
442.10K
Relative Volume:
1.58
Capitalizzazione di mercato:
$188.40M
Reddito:
-
Utile/perdita netta:
$-52.07M
Rapporto P/E:
-38.23
EPS:
-0.2077
Flusso di cassa netto:
$-44.93M
1 W Prestazione:
-7.46%
1M Prestazione:
-4.57%
6M Prestazione:
-21.39%
1 anno Prestazione:
-21.00%
Intervallo 1D:
$7.55
$7.9699
Intervallo di 1 settimana:
$7.28
$9.83
Portata 52W:
$4.81
$13.88
Cybin Inc Stock (CYBN) Company Profile
Nome
Cybin Inc
Settore
Industria
Telefono
908 764 8385
Indirizzo
100 King Street West, Suite 5600, Toronto
Confronta CYBN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
7.94 | 188.40M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Guggenheim | Buy |
| 2021-11-19 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Borsa (CYBN) Ultime notizie
Cybin CEO Doug Drysdale: Revolutionizing Depression Treatment - worth.com
Psychedelic Industry Summit: Top CEOs and Investors Unite to Shape $Billion Market Future - Stock Titan
Cybin Provides Corporate Update and Highlights Positive Regulato - GuruFocus
# Cybin begins phase 3 trials for depression treatment CYB003 By Investing.com - Investing.com South Africa
Silicon Valley - FinancialContent
Cybin Advances Phase 3 Program Amid Positive Regulatory Signals - TipRanks
# Cybin begins phase 3 trials for depression treatment CYB003 - Investing.com Australia
Cybin Provides Corporate Update, Highlights Positive Regulatory Signals For Psychedelic Therapeutics - MarketScreener
Should You Buy Polkadot While It's Under $5? - The Globe and Mail
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics - Business Wire
Prediction: This Company Will Be the Most Valuable AI Stock in 2026 - The Globe and Mail
Billionaire Bill Ackman Just Scooped Up Shares of This Unstoppable Stock - The Globe and Mail
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Per - GuruFocus
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference | CYBN Stock News - GuruFocus
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference - The Globe and Mail
Cybin to Participate in the 2025 Psychedelic Science Conference - GuruFocus
Cybin to Participate in the 2025 Psychedelic Science Conference | CYBN Stock News - GuruFocus
Crypto's hottest new trend: publicly traded companies buying bunches of bitcoin - The Globe and Mail
(CYBN) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Cybin, Inc: The Strategic Approach to Formulating a Successful CYB003 Launch - Smartkarma
Cybin (CYBN) Gains Positive Outlook from Lucid Capital | CYBN St - GuruFocus
Market Analysis: June 6th, 2025 - The Globe and Mail
lucid capital markets initiates buy rating on cybin stock - Investing.com Australia
lucid capital markets initiates buy rating on cybin stock By Investing.com - Investing.com South Africa
Cybin (CYBN) Gains Positive Outlook from Lucid Capital | CYBN Stock News - GuruFocus
Cybin secures U.S. patent for program targeting generalized Anxiety disorder and depression - Proactive Investors
Cybin, Inc.The Strategic Approach to Formulating a Successful CYB003 Launch - Smartkarma
Massive News for DraftKings Stock Investors - The Globe and Mail
Psychedelic Drugs Market 2025 | Growth Trends, Mental Health - openPR.com
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder - BioSpace
Cybin secures patent for anxiety disorder treatment CYB004 - Investing.com
Cybin Granted Additional US Patent for Potential Anxiety Disorder Treatments - MarketScreener
Cybin secures patent for anxiety disorder treatment CYB004 By Investing.com - Investing.com Canada
Cybin Secures U.S. Patent for CYB004 Program in Anxiety Disorder Treatment - TipRanks
Cybin (CYBN) Secures U.S. Patent for CYB004 Program | CYBN Stock News - GuruFocus
Cybin Announces Additional U.S. Patent Supporting its CYB004 Pro - GuruFocus
Will Blue Chip UPS Deliver for Shareholders? - The Globe and Mail
Cybin taps Thermo Fisher for U.S. manufacturing of CYB003 - MSN
Transcript : Cybin Inc.Special Call - marketscreener.com
(CYBN) Proactive Strategies - news.stocktradersdaily.com
Prediction: Dogecoin Will Plummet to New Lows by the End of the Year. Here's Why. - The Globe and Mail
Cboe Canada Single Security - Cboe Global Markets
Billionaire CEO Jamie Dimon Just Delivered a Stark Warning to the Market. Here Are 3 Things Investors Should Do. - The Globe and Mail
This Chinese Robotaxi Stock Could Be an Even Better Buy Than Tesla Before June - The Globe and Mail
Cybin CEO to Discuss Strategic Advances at Upcoming Fireside Chat - TipRanks
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025 - BioSpace
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025 | CYBN Stock News - GuruFocus
Cybin CEO Reveals Latest on Phase 3 Psychedelics Program and FDA Developments in Exclusive Analyst Chat - Stock Titan
Cybin Inc Azioni (CYBN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.68%
0.50%
Capitalizzazione:
|
Volume (24 ore):